Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2014-05-12 Earnings Release
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text specifically mentions that the company issued a press release announcing first quarter financial results and an upcoming investor conference call to discuss these results and business outlook. The document itself does not contain detailed financial statements or comprehensive analysis but rather announces the results and the call. The length is 2677 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results.
2014-05-12 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2014-04-23 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement filed on Schedule 14A with the SEC, related to the solicitation of proxies for the Annual Meeting of Stockholders of TG Therapeutics, Inc. It includes detailed information about the meeting agenda, voting instructions, board of directors, executive compensation, and other governance matters. The document is not an annual report, earnings release, or financial statement, but rather a proxy solicitation document. According to the filing definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), and it contains the full proxy statement, not just an announcement or notice. Therefore, the correct classification is PSI with high confidence.
2014-04-11 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 17, 2014. It details an underwriting agreement for the sale of common stock shares, including legal and accounting fees related to the transaction. The document includes an opinion letter from counsel as an exhibit. The content focuses on a financing transaction and related disclosures rather than full financial statements or earnings results. The document length is 3456 characters, which is relatively short and consistent with a current report rather than a full annual or quarterly report. The primary subject is a capital raising event through share issuance, which aligns with a Capital/Financing Update. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-03-17 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically references an underwriting agreement dated March 11, 2014, between TG Therapeutics, Inc. and Ladenburg Thalmann & Co. Inc. This indicates a financing or capital raising event. The document is short (2321 characters) and focuses on the underwriting agreement, which is related to capital or financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2014-03-12 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement related to a common stock offering by TG Therapeutics, Inc. It details the terms of the offering, including number of shares, pricing, underwriting, use of proceeds, risk factors, and other offering-related information. This type of filing is a capital raising document filed with the SEC to inform investors about a new share issuance. It is not a financial report, earnings release, management discussion, or any other type of report. It is specifically a prospectus supplement related to a capital raising event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, consistent with a capital/financing update filing.
2014-03-12 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.